Walid Abu Arab1,2*, Yves Collin1, Marco Sirois1, Marc-André Levasseur3 and Nancy Paquet3Fulltext PDF
Background: Carcinoid tumors are rare low grade neuroendocrine tumors which rarely affect the lung. Somatostatin - receptor scintigraphy (Octreo-scan) can be helpful in the diagnosis and staging when the tumor is located in the gastro-intestinal tract (GI-tract). However, there is a few data in the literature regarding its role in the diagnosis of pulmonary carcinoids. The aim of this study is to assess the clinical utility of Somatostatin Receptor Scintigraphy (SRS) [OctreoScan®*] in the diagnosis and staging of pulmonary carcinoids and its role in the treatment plan of the patients.Methods: This is a retrospective clinical study that included the patients with pulmonary carcinoid tumors who underwent lung resection at Centre HospitalierUniversitaire de Sherbrooke (CHUS), Canada between 2004 and 2014. The files of those patients have been reviewed. Data collected included the demographic data, methods of diagnosis, pathology, staging work-up as well as costs of the effectuated investigations. Statistical analysis of was performed using Microsoft Excel 2007.Results: Sixteen patients were included in this study. SRS was performed for eight of them, and it was positive in seven patients (87% sensitivity). On contrast, Positive Emission Tomography (PETscan) was found to have 76% sensitivity. The cost was 1100 CAN$ for PET-scan and 2000 CAN$ for SRS. Radiation dose equivalence were comparable for both exams.Conclusions: The SRS is a valuable method to detect and stage pulmonary carcinoid tumors. We believe that it should be the method of choice for a diagnosis and staging when pulmonary carcinoid tumor is suspected.
Lung Cancer; Diagnosis of carcionoid; Neuroendocrine; Neuroendocrine tumor; Positron Emission Tomography PET; Octreoscan; SRS
Arab WA, Collin Y, Sirois M, Levasseur M-A, Paquet N. The Role of Somatostatin-Receptor Scintigraphy in the Diagnosis and Staging of Pulmonary Carcinoid Tumors. Clin Oncol. 2018; 3: 1391.